Piramal Pharma posts Q4 FY23 consolidated PAT at Rs. 50.11 Cr

The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023

Piramal Pharma starts production at new API facility in Riverview, Michigan

New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)

Briefs: Piramal Pharma, Alembic Pharmaceuticals

USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA

USFDA conducts PAI and GMP inspection of Piramal Pharma's Sellersville facility

The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations

USFDA inspects Piramal Pharma Lexington facility

The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.

Piramal Pharma Solutions launches ADCelerate

ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission

Piramal Pharma appoints Vibha Paul Rishi as Non- Executive Director

Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada

Plant is part of the company's CAD $30 million capital investment in the site

Piramal Pharma strengthens board by inducting three new board members

The appointments will add to the well-diversified experience that currently exists on the PPL board.

Piramal Pharma Solutions appoints Herve Berdou as COO

Brings 25 years of global operations and supply chain experience to Piramal